Ad
related to: pde5 inhibitors for bph symptoms in dogs
Search results
Results From The WOW.Com Content Network
Silodosin has high affinity for the alpha 1A-adrenergic receptor in the prostate, the bladder, and the prostatic urethra. By this mechanism, it relaxes the smooth muscles in these organs, easing urinary flow and other symptoms of benign prostatic hyperplasia. [4]
Phosphodiesterase-5. A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
A phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a vasodilating drug that works by blocking the degradative action of cGMP-specific phosphodiesterase type 5 (PDE5) on cyclic GMP in the smooth muscle cells lining the blood vessels supplying various tissues.
PDE5 inhibitors like Cialis are the first line of treatment for ED. They can help you get an arousal by relaxing the blood vessels in your privates and boosting blood flow to the area .
Osaterone acetate is used in veterinary medicine for the treatment of benign prostatic hyperplasia (BPH) in dogs. [3] [5] [6] It has been found to produce remission of clinical symptoms of BPH in 83% of dogs for six months after a single one-week course of treatment, [9] and can be used long-term.
Adibendan; Aminophylline; Aminophylline dihydrate; Amipizone; Apremilast; Arofylline; Atizoram; Befuraline; Bemarinone hydrochloride; Bemoradan; Benafentrine; Bucladesine
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
The PDE5 inhibitors sildenafil, vardenafil and tadalafil are competitive and reversible inhibitors of cGMP hydrolysis by the catalytic side of PDE5. The structures of vardenafil and sildenafil are similar, they both contain similar structured purine ring of cGMP that contributes their features to act as a competitive inhibitor of PDE5.